Awaiting product image

Infectious Disease Diagnostics: World Market Analysis: HIV/AIDS, Hepatitis, Tuberculosis, STDs, HAIs, ID/AST, Influenza, TORCH, Other

$5,500.00 – $11,000.00

SKU: 19-030 Categories: , , , , Tags: , , , , , , , Pages: 202

Description

Infectious disease testing comprises one of the largest and fastest growing applications served by the global in vitro diagnostics (IVD) industry. Most of the leading industry competitors as well as a sizable number of specialized IVD concerns are active in this product segment. The detection and characterization of infectious diseases hold promising worldwide growth potential as discussed in Kalorama’s Infectious Disease Diagnostics: World Market Analysis: HIV/AIDS, Hepatitis, Tuberculosis, STDs, HAIs, ID/AST, Influenza, TORCH, Other.

The World Infectious Disease Testing Market

Global demand for infectious disease testing products in 2018 had applications extending into nine major segments:

  • Sexually transmitted diseases other than hepatitis and HIV/AIDS (including chlamydia, gonorrhea, herpes HSV-1 and HSV-2, human papillomavirus, syphilis, and trichomoniasis)
  • Hepatitis
  • HIV/AIDS
  • Healthcare-associated infections (HAIs), including sepsis, MRSA, C. difficile, VRE, and others
  • Antibiotic susceptibility testing
  • Influenza
  • Tuberculosis
  • TORCH
  • Others (including malaria, dengue fever, foodborne infections, Lyme disease, RSV, Strep A, and typhoid)

Infectious diseases are ailments caused by pathogenic microorganisms that invade the body, either directly or indirectly via afflicted carriers or contaminated sources. IVD tests for these conditions are designed to detect and identify the responsible pathogen, pinpoint its origin, and determine an appropriate antimicrobial therapy. Infectious disease IVD products include reagents, consumables, and instruments based primarily on immunoassays, molecular technologies, and conventional microbiology techniques. Specific types of tests are available for detecting hundreds of pathogenic conditions. The report examines the global demand for infectious disease IVD products, which is projected to increase as medical providers and healthcare organizations throughout the world heighten efforts to combat proliferating epidemic threats. Data provided include the following:

  • World Infectious Disease Diagnostic Test Market, 2018-2026 ($ millions)
  • Global Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Demand)
  • Global Sexually Transmitted Disease (STD) IVD Demand by Test Type & Condition 2018 – 2026 (million dollars) (By Type of Test: Immunoassay, Molecular, Other; By Condition: Chlamydia, HPV, Gonorrhea, Herpes HSV-2, Syphilis, Other; Global STD IVD Demand)
  • Global Hepatitis IVD Demand by Test Type 2018 – 2026 (million dollars) (Laboratory Tests, Blood Screening, POC Tests, Global Hepatitis IVDs)
  • Global HIV/AIDS IVD Demand by Test Type 2018 – 2026 (million dollars) (Laboratory Tests, Blood Screening, POC Tests, Global HIV/AIDS IVDs)
  • Global Healthcare-Associated Infections (HAIs) IVD Demand by Test Type & Condition 2018 – 2026 (million dollars) (By Type of Test: Immunoassay, Molecular, Microbiology; By Condition: C. diff, Sepsis, MRSA, VRE, Other HAIs; Global HAIs IVDs)
  • Identification/Antibiotic Susceptibility Testing (ID/AST) Demand by Test Type 2018 – 2026 (million dollars) (Automated Tests, Manual Tests, Global ID/AST)
  • Global Influenza Testing IVD Demand by Test Type 2018 – 2026 (million dollars) (Rapid ID Tests, Molecular Tests, Other Tests, Global Influenza IVDs)
  • Global Tuberculosis (TB) Testing IVD Demand by Test Type 2018 – 2026 (million dollars) (Microbiology Tests, POC Tests, Molecular Tests, Global Tuberculosis IVDs)
  • Global TORCH-Related IVD Demand 2018 – 2026 (million dollars)
  • Global Other Infectious Disease IVD Demand by Condition 2018 – 2026 (million dollars) (Malaria, Streptococcal Infections, Lyme Disease, Fungal Infections, Parasitic Conditions, RSV, Emerging Infections, Dengue Fever, All Other Conditions, Global Other Infection IVDs)

The report also reviews various infectious disease testing technologies (immunoassay, microbiology, and molecular), markets (hospital and independent testing laboratories, POC and POL laboratories, blood banks, and other end-users), and products (reagents and consumables and instruments):

  • Global Infectious Disease IVD Reagents, Consumables, & Instruments Demand 2018 – 2026 (million dollars) (Reagents/Consumables: STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH-Related, Other; Instruments & Systems; Global infection IVDs)
  • Global Infectious Disease IVD Demand by Technology 2018 – 2026 (million dollars) (Immunoassay, Molecular, Microbiology & Related, Global Infection IVDs)
  • Global Infectious Disease IVD Demand by End-Use Market 2018 – 2026 (million dollars) (Hospitals, Clinical Laboratories, POC Laboratories, Other Markets, Global Infection IVDs)

Geographic and Country Markets

Based on a high level of national health expenditures and patient activity and the large role played by private medical providers in the healthcare system, the U.S. will remain the largest and most diversified infectious disease testing market. China and India will provide the fastest growth among the developing economies as diagnostic capabilities are expanded and upgraded. Infectious Disease Diagnostics: World Market Analysis analyzes geographic and country markets, including North America: United States, Canada, Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Central & South America; Eastern Europe; Middle East; and Africa.

  • Global Infectious Disease IVD Demand by Country/Region 2018 – 2026 (million dollars) (North America: United States, Canada & Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Cent & So America; Eastern Europe; Middle East; Africa; Total World)
  • North America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total N Amer)
  • United States – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total US)
  • Canada – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Canada)
  • Mexico – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Mexico)
  • Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total W. Europe)
  • Germany – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Germany)
  • France – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total France)
  • United Kingdom – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total UK)
  • Italy – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Italy)
  • Spain – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Spain)
  • Other Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total OWE)
  • Other Western Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Netherlands, Belgium, Austria, Sweden, Switzerland, Denmark, Portugal, Norway, Greece, Ireland, Finland, All Other)
  • Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Asia/Pacific)
  • China – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total China)
  • Japan – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Japan)
  • India – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total India)
  • South Korea – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total South Korea)
  • Australia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Australia)
  • Other Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Other Asia/Pacific)
  • Other Asia/Pacific – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Indonesia, Taiwan, Thailand, Philippines, Vietnam, Malaysia, Pakistan, Hong Kong, Singapore, New Zealand, All Other)
  • Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total C & S Amer)
  • Brazil – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Brazil)
  • Other Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Cent & So Amer)
  • Other Central & South America – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Argentina, Colombia, Chile, Peru, Venezuela, All Other)
  • Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total E Europe)
  • Russia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Russia)
  • Other Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other E. Europe)
  • Other Eastern Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Poland, Romania, Czechia, Ukraine, Hungary, All Other)
  • Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Middle East)
  • Turkey – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Turkey)
  • Other Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Middle East)
  • Other Middle East – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Iran, Saudi Arabia, Iraq, Israel, UAE, All Other)
  • Africa – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Africa)
  • Africa – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Egypt, South Africa, Nigeria, All Other)

Market Drivers

The report looks at market drivers, including external market influences that are promoting the development and use of improved infectious disease diagnostics. Public health officials worldwide have begun to recognize the global nature of infectious diseases – they are no longer solely a problem of developing countries but touch the very fabric of the social and economic welfare of countries in the industrialized world as well. Over the long term, aging populations and problems posed by infectious diseases will strain healthcare resources in many countries.

Competitive Landscape

The report details the major competitors that are global market leaders in infectious disease testing products and technologies, including an overview and an outline of these company’s infectious disease IVD products:

  • ABL SA
  • Abbott Laboratories
  • Becton, Dickinson and Company (BD)
  • bioMérieux Inc.
  • Bio-Rad Laboratories, Inc.
  • Curetis N.V.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • EKF Diagnostics Holdings plc
  • Fujirebio Inc.
  • Grifols
  • Hologic, Inc.
  • InSilixa, Inc.
  • Meridian Bioscience, Inc.
  • OraSure Technologies, Inc.
  • Ortho-Clinical Diagnostics
  • QIAGEN N.V.
  • Quidel Corporation
  • Roche
  • Siemens AG
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech

The information presented herein is derived from publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author’s industry knowledge combined with literature searches and selected direct interviews with industry experts conducted previously.

Estimates in the report are based on an examination of epidemiological statistics, test pricing, annual reports of key competitors and regional sales, as well as Kalorama Information’s databases and economic composites.

Table of Contents

1: EXECUTIVE SUMMARY
A Mix of Traditional and Emerging Testing Technologies
Market Drivers
The World Infectious Disease Testing Market

  • Table 1-1 | World Infectious Disease Diagnostic Test Market, 2018-2026 ($ millions)

Major Findings of the Report

  • Table 1-2 | Selected Infectious Diseases, Global Incidence, Prevalence, & Mortality, 2018 (Sexually Transmitted Diseases: Trichomoniasis, Herpes HSV-1, Chlamydia, Gonorrhea, Syphilis; Malaria; Dengue Fever [Severe Cases]; Hepatitis [all forms]; Sepsis; Typhoid Fever; Tuberculosis; Influenza; AIDS/HIV; HPV)

Scope and Methodology

2. MARKET ENVIRONMENT
Overview

  • Table 2-1 | Global Healthcare Indicators 2018 – 2026

Global Macroeconomic Environment

  • Global Economic Outlook
    • Table 2-2 | Global Gross Domestic Product by Country/Region 2018 – 2026 (trillion dollars)
  • Per Capita Gross Domestic Product
    • Table 2-3 | Global Per Capita Gross Domestic Product by Country/Region 2018 – 2026 (dollars)

    Demographic Trends

  • Total Population
    • Table 2-4 | Global Population by Country/Region 2018 – 2026 (million persons)
  • Age Distribution
    • Table 2-5 | Global Population 50 Years & Older by Country/Region 2018 – 2026 (million persons)
    • Table 2-6 | Global Population 65 Years & Older by Country/Region 2018 – 2026 (million persons)
    • Table 2-7 | Global Percentage of Population 65 Years & Older by Country/Region 2018 – 2026

    Global Healthcare Trends

  • Health Expenditures
    • Table 2-8 | Global Health Expenditures by Country/Region 2018 – 2026 (billion dollars)
    • Table 2-9 | Global Per Capita Health Expenditures by Country/Region 2018 – 2026 (dollars)
  • Hospitals
    • Table 2-10 | Global Number of Hospitals by Country/Region 2018 – 2026 (thousand)
    • Table 2-11 | Global Number of Hospital Beds by Country/Region 2018 – 2026 (thousand)
  • Physicians
    • Table 2-12 | Global Number of Physicians by Country/Region 2018 – 2026 (thousand)
  • Clinical Laboratories

Patient Activity

  • Table 2-13 | Global Number of Hospital Admissions by Country/Region 2018 – 2026 (million)
  • Table 2-14 | Global Number of Inpatient Days by Country/Region 2018 – 2026 (million)
  • Table 2-15 | Global Number of Surgical Procedures by Country/Region 2018 – 2026 (million)
  • Table 2-16 | Global Number of Outpatient Consultations by Country/Region 2018 – 2026 (million)
  • Table 2-17 | Global Number of IVD Tests by Country/Region 2018 – 2026 (million) (North America: United States, Canada & Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Cent & So America; Eastern Europe; Middle East; Africa; Total World)

3. INFECTIOUS DISEASE IVD PRODUCT MARKETS
Overview

  • Table 3-1 | Global Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Demand)

Sexually Transmitted Diseases (STDs)

  • Table 3-2 | Global Sexually Transmitted Disease (STD) IVD Demand by Test Type & Condition 2018 – 2026 (million dollars) (By Type of Test: Immunoassay, Molecular, Other; By Condition: Chlamydia, HPV, Gonorrhea, Herpes HSV-2, Syphilis, Other; Global STD IVD Demand)
  • Chlamydia Trachomatis (chlamydia)
  • Human Papillomavirus (HPV)
  • Gonorrhea
  • Herpes Simplex Virus 2 (HSV-2)
  • Syphilis
  • Other Sexually Transmitted Disease (STD) IVD Products
    Hepatitis IVD Products

    • Table 3-3 | Global Hepatitis IVD Demand by Test Type 2018 – 2026 (million dollars) (Laboratory Tests, Blood Screening, POC Tests, Global Hepatitis IVDs)

    HIV/AIDS IVD Products

    • Table 3-4 | Global HIV/AIDS IVD Demand by Test Type 2018 – 2026 (million dollars) (Laboratory Tests, Blood Screening, POC Tests, Global HIV/AIDS IVDs)

    Healthcare-Associated Infections (HAIs) IVD Products

  • Clostridium difficile (C. diff)
    • Table 3-5 | Global Healthcare-Associated Infections (HAIs) IVD Demand by Test Type & Condition 2018 – 2026 (million dollars) (By Type of Test: Immunoassay, Molecular, Microbiology; By Condition: C. diff, Sepsis, MRSA, VRE, Other HAIs; Global HAIs IVDs)
  • Sepsis
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • Vancomycin-Resistant Enterococcus (VRE)
  • Other HAIs
    Antibiotic Susceptibility Testing (AST) Products

    • Table 3-6 | Identification/Antibiotic Susceptibility Testing (ID/AST) Demand by Test Type 2018 – 2026 (million dollars) (Automated Tests, Manual Tests, Global ID/AST)

    Influenza

    • Table 3-7 | Global Influenza Testing IVD Demand by Test Type 2018 – 2026 (million dollars) (Rapid ID Tests, Molecular Tests, Other Tests, Global Influenza IVDs)

    Tuberculosis (TB)

    • Table 3-8 | Global Tuberculosis (TB) Testing IVD Demand by Test Type 2018 – 2026 (million dollars) (Microbiology Tests, POC Tests, Molecular Tests, Global Tuberculosis IVDs)

    TORCH

    • Table 3-9 | Global TORCH-Related IVD Demand 2018 – 2026 (million dollars)

    All Other Infectious Disease IVD Products

    • Table 3-10 | Global Other Infectious Disease IVD Demand by Condition 2018 – 2026 (million dollars) (Malaria, Streptococcal Infections, Lyme Disease, Fungal Infections, Parasitic Conditions, RSV, Emerging Infections, Dengue Fever, All Other Conditions, Global Other Infection IVDs)
  • Malaria
  • Streptococcal Infections
  • Lyme Disease
  • Fungal Infections
  • Parasitic Conditions
  • Respiratory Syncytial Virus (RSV)
  • Emerging Infections
  • Dengue Fever
  • Additional Products
    Global Infectious Disease IVD Demand by Major Product Group

    • Table 3-11 | Global Infectious Disease IVD Reagents, Consumables, & Instruments Demand 2018 – 2026 (million dollars) (Reagents/Consumables: STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH-Related, Other; Instruments & Systems; Global infection IVDs)

    Global Infectious Disease IVD Demand by Technology

    • Table 3-12 | Global Infectious Disease IVD Demand by Technology 2018 – 2026 (million dollars) (Immunoassay, Molecular, Microbiology & Related, Global Infection IVDs)
  • Molecular Technologies
  • Immunoassays

Conventional Microbiology
Global Infectious Disease IVD Demand by Market

  • Table 3-13 | Global Infectious Disease IVD Demand by End-Use Market 2018 – 2026 (million dollars) (Hospitals, Clinical Laboratories, POC Laboratories, Other Markets, Global Infection IVDs)

4. GLOBAL MARKETS

  • Table 4-1 | Global Infectious Disease IVD Demand by Country/Region 2018 – 2026 (million dollars) (North America: United States, Canada & Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Cent & So America; Eastern Europe; Middle East; Africa; Total World)

North America

  • Table 4-2 | North America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total N Amer)
  • United States
    • Table 4-3 | United States – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total US)
  • Canada
    • Table 4-4 | Canada – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Canada)
  • Mexico
    • Table 4-5 | Mexico – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Mexico)

Western Europe

  • Table 4-6 | Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total W. Europe)
  • Germany
    • Table 4-7 | Germany – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Germany)
  • France
    • Table 4-8 | France – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total France)
  • United Kingdom
    • Table 4-9 | United Kingdom – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total UK)
  • Italy
    • Table 4-10 | Italy – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Italy)
  • Spain
    • Table 4-11 | Spain – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Spain)
  • Other Western Europe
    • Table 4-12 | Other Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total OWE)
    • Table 4-13 | Other Western Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Netherlands, Belgium, Austria, Sweden, Switzerland, Denmark, Portugal, Norway, Greece, Ireland, Finland, All Other)

Asia/Pacific

  • Table 4-14 | Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Asia/Pacific)
  • China
    • Table 4-15 | China – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total China)
  • Japan
    • Table 4-16 | Japan – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Japan)
  • India
    • Table 4-17 | India – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total India)
  • South Korea
    • Table 4-18 | South Korea – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total South Korea)
  • Australia
    • Table 4-19 | Australia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Australia)
  • Other Asia/Pacific
    • Table 4-20 | Other Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Other Asia/Pacific)
    • Table 4-21 | Other Asia/Pacific – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Indonesia, Taiwan, Thailand, Philippines, Vietnam, Malaysia, Pakistan, Hong Kong, Singapore, New Zealand, All Other)

     

Central & South America

  • Table 4-22 | Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total C & S Amer)
  • Brazil
    • Table 4-23 | Brazil – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Brazil)
  • Other Central & South America
    • Table 4-24 | Other Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Cent & So Amer)
    • Table 4-25 | Other Central & South America – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Argentina, Colombia, Chile, Peru, Venezuela, All Other)

     

Eastern Europe

  • Table 4-26 | Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total E Europe)
  • Russia
    • Table 4-27 | Russia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Russia)
  • Other Eastern Europe
    • Table 4-28 | Other Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other E. Europe)
    • Table 4-29 | Other Eastern Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Poland, Romania, Czechia, Ukraine, Hungary, All Other)

     

Middle East

  • Table 4-30 | Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Middle East)
  • Turkey
    • Table 4-31 | Turkey – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Turkey)
  • Other Middle East
    • Table 4-32 | Other Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Middle East)
    • Table 4-33 | Other Middle East – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Iran, Saudi Arabia, Iraq, Israel, UAE, All Other)

     

Africa

  • Table 4-34 | Africa – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Africa)
  • Table 4-35 | Africa – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Egypt, South Africa, Nigeria, All Other)

5. COMPANY PROFILES
ABL SA

  • Overview
  • Infectious Disease IVD Products

Abbott Laboratories

  • Overview
  • Infectious Disease IVD Products

Becton, Dickinson and Company (BD)

  • Overview
  • Infectious Disease IVD Products

bioMérieux Inc.

  • Overview
  • Infectious Disease IVD Products

Bio-Rad Laboratories, Inc.

  • Overview
  • Infectious Disease IVD Products

Curetis N.V.

  • Overview
  • Infectious Disease IVD Products

Danaher Corporation

  • Overview
  • Infectious Disease IVD Products

DiaSorin S.p.A.

  • Overview
  • Infectious Disease IVD Products

EKF Diagnostics Holdings plc
Fujirebio Inc.

  • Overview
  • Infectious Disease IVD Products

Grifols

  • Overview
  • Infectious Disease IVD Products

Hologic, Inc.

  • Overview
  • Infectious Disease IVD Products

InSilixa, Inc.
Meridian Bioscience, Inc.

  • Overview
  • Infectious Disease IVD Products

OraSure Technologies, Inc.

  • Overview
  • Infectious Disease IVD Products

Ortho-Clinical Diagnostics

  • Overview
  • Infectious Disease IVD Products

QIAGEN N.V.

  • Overview
  • Infectious Disease IVD Products

Quidel Corporation

  • Overview
  • Infectious Disease IVD Products

Roche

  • Overview
  • Infectious Disease IVD Products

Siemens AG

  • Overview
  • Infectious Disease IVD Products

T2 Biosystems, Inc.

  • Overview
  • Infectious Disease IVD Products

Thermo Fisher Scientific Inc.

  • Overview
  • Infectious Disease IVD Products

Trinity Biotech

  • Overview
  • Infectious Disease IVD Products

Related products

Sexually Transmitted Disease (STD) Testing Markets (Test Services, Diagnost...Biosimilar Market Trends 2019